MPM Oncology Impact Management »

Morphic Hldg shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Morphic Hldg (MORF) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Morphic Hldg

Tip: Access up to 7 years of quarterly data

All positions including Morphic Hldg held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Morphic Hldg by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $4.6M 200k 22.91

More positions owned by MPM Oncology Impact Management

Cullinan Oncology Common (CGEM)
Olema Pharmaceuticals Common (OLMA)
Geron Corporation Common (GERN)
Repare Therapeutics Common (RPTX)
iTeos Therapeutics Common (ITOS)
Intellia Therapeutics Common (NTLA)
Moonlake Immunotherapeutics Common (MLTX)
Iovance Biotherapeutics Common (IOVA)
Crinetics Pharmaceuticals Common (CRNX)
Insmed Incorporated Common (INSM)
Structure Therapeutics Common (GPCR)
Verve Therapeutics Common (VERV)
Relay Therapeutics Common (RLAY)
Regenxbio Common (RGNX)
Cymabay Therapeutics Common

View all positions for MPM Oncology Impact Management

Top funds holding Morphic Hldg

Point72 Asset Management
Wellington Management Company
BlackRock
Vanguard Group
T. Rowe Price Associates
Artal Group
Federated Investors
Goldman Sachs Group
Two Sigma Advisers
Two Sigma Investments
Marshall Wace
Charles Schwab Investment Management
Omega Fund Management
D. E. Shaw & Co
Bank of America Corporation

View all funds holding Morphic Hldg